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Gram-positive and nonpathogenic lactic acid bacteria 
(LAB) are considered to be promising candidates for 
the development of new, safe systems of heterologous 
protein expression. Recombinant LAB has been shown 
to induce specific local and systemic immune response 
against selected pathogens, and could be a good alter-
native to classical attenuated carriers. The main goal of 
our study was to express the avian influenza haemagglu-
tinin (H5) and chicken interleukin 2 (chIL-2) in Lactococ-
cus lactis. Results of this study were anticipated to lead 
to construction of lactococcal strain(s) with potential 
vaccine properties against the avian influenza A (H5N1) 
virus. Expression of the cloned H5 gene, its His-tagged 
variant and chIL-2 gene, under the control of the ptcB 
gene promoter was attested by RT-PCR on transcription-
al level and Western or dot blot analysis on translational 
level, demonstrating that system can be an attractive 
solution for production of heterologous proteins. The 
results of the preliminary animal trial conducted in mice 
are a promising step toward development of a vaccine 
against avian bird flu using Lactococcus lactis cells as an-
tigen carriers.
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INTRODUCTION
Lactic acid bacteria (LAB) are non-invasive and non-
pathogenic Gram-positive bacteria with a GRAS (gener-
ally regarded as safe) status, widely used for food-pro-
cessing and preservation. Due to their long and safe 
association with humans, rapid growth, small genomes 
and simple metabolism, LAB are considered to be prom-
ising candidates for controlled and targeted administra-
tion of vaccine antigens to the mucosal immune system 
(Le Loir et al., 1998; Geoffroy et al., 2000; Enouf et al., 
2001; Bermudez-Humaran et al., 2002). For this, bacte-
ria are specifically engineered to obtain recombinants, 
which can induce a specific local and systemic immune 
response against selected pathogens. The properties of 
many LAB include: gastric acid and bile salts tolerance, 
antagonistic properties against pathogenic microorgan-
isms and ability to adhere to the gut epithelium, which 
makes them useful for oral immunization (Titgemeyer 
& Hillen, 2002; Mota et al., 2006). Lactococcus lactis is a 
non-invasive and non-commensal lactic acid bacterium 
with low potential to trigger immunotolerance or side 
effects upon prolonged use (Perdigon et al., 2001). Fur-
thermore, L. lactis elicits only a weak immune response 
against itself, despite its ability to act as an immunoad-
juvant to accompanying antigens (Drouault et al., 1999; 
Guillemin et al., 2009). During the past two decades a re-
markable progress has been made toward the molecular 
characterization of L. lactis and development of genetic 
engineering tools (Gasson & Vos, 1994; Underdown & 
Mestecky, 1994; Wood & Warner, 2003; Wegmann et al., 
2007; Wells & Mercenier, 2008). Moreover, L. lactis has 
been extensively engineered for production of heterolo-
gous proteins, including some antigens of bacterial or vi-
ral origin (Sanchez et al., 2008). Promising results have 
been obtained for various antigens administered via dif-
ferent routes using L. lactis as a delivery vehicle (Ribeiro 
et al., 2002; Ramasamay et al., 2006). 
The study presented here describes preliminary ex-
periments using L. lactis engineered for production of 
the major avian influenza virus (H5N1) antigen - viral 
haemagglutinin (H5) and chicken interleukin 2 (chIL-2), 
based on the ptcB promoter system. Haemagglutinin is 
the major protein of the influenza virus capable of in-
ducing antibody production in the infected host. ChIL-2 
is a glycoprotein produced by T-type lymphocytes under 
the influence of specific and nonspecific mitogens. It 
induces proliferation of the T helper and suppressor as 
well as cytotoxic cells and enhances the activity of NK 
cells. Due to such properties, it can be used in designed 
vaccines as a natural adjuvant (Lillehoj et al., 2001). 
Our study sets the basis for development of a L. lactis 
strain(s) with potent vaccine properties against avian in-
fluenza A (H5N1) virus. 
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MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacteria 
and plasmids used in this study are listed in Table 1. 
Bacterial cells were cultured at 30°C in M17 broth (Ter-
zaghi & Sandine, 1975) containing 0.5% glucose (GM17) 
without shaking or on GM17 plates with 1.5% agar. 
Erythromycin (Boehringer GmbH, Mannheim, Germany) 
was added to a concentration of 5 µg ml–1, where nec-
essary. For induction of protein synthesis, transformed 
cells were cultured overnight at 30°C in a chemically 
defined medium (CDM) containing 0.5% cellobiose and 
erythromycin (5 µg ml–1 final concentration). 
DNA manipulation and transformation. The analy-
sis was carried out by CODONW 1.4.2 (http://codonw.
sourceforge.net/). Codon usage in the nucleotide se-
quence of both H5 and chIL-2 appeared to be compat-
ible with codons preferred by L. lactis. DNA molecular 
cloning and restriction enzyme analysis were performed 
according to general procedures (Staats et al., 1994). 
L. lactis cells were made electrocompetent for transfor-
mation with the pIL253:PptcB vector or its recombinant 
variants as already described (Holo & Nes, 1989; Wells et 
al., 1993). Plasmid DNA from L. lactis was isolated using 
PureYield plasmid mini-prep system (Promega) and a 
protocol modified for L. lactis where lysozyme was add-
ed (10 mg×ml–1) prior to the lysis step and incubating 
the cell suspension for 30 min at 37°C to generate pro-
toplasts. 
Amplification of H5 and chIL-2 DNA genes by 
polymerase chain reaction (PCR). H5 [H5N1 A/
swan/Poland/305-135V08/2006 strain from AIV Epi-
FluDatabase [http://platform.gisaid.org]; Accession No. 
EP1156789], H5 with a C-terminal His-tag and chIL-2 
[GenBank AF017645] genes were amplified using a stan-
dard PCR technique employing cDNA as template and 
specific primers listed in Table 1. 
Cloning of avian influenza virus H5 and chick-
en IL-2 genes in pIL253:PptcB vector. Recombinant 
plasmids were created by ligation of pIL253:PptcB vector 
with the 1.8-kb H5 gene PCR product or its his-tagged 
derivative, previously digested with BamHI/XhoI re-
strictases. Construct carrying additionally the chIL-2 gene 
downstream of the H5 gene was generated by digesting 
the 434-bp chIL-2 PCR product with BoxI and ligating 
it with pIL253:PptcB:H5, prepared in the same way. Re-
combinant constructs were selected by colony PCR, with 
one primer specific for the insert, and the second one - 
specific for the plasmid sequence. Inserts in each clone 
were sequenced (GS FLX Titanium 454, Roche) to con-
firm their identity with the templates used. 
Isolation of total RNA from L. lactis. RNA samples 
were isolated from logarithmic-phase L. lactis cultures 
grown on CDM medium supplemented with 0.5% cello-
biose using commercial RNeasy mini Kit (Qiagen). RNA 
samples were stored at –80ºC prior to further use. 
Reverse transcription analysis. Reverse transcription 
(RT) reaction was performed with the SuperScriptTM III 
reverse transcriptase kit (Invitrogen), according to the 
manufacturer’s instructions, using an appropriate reverse 
primer (Table 1). Specific cDNA was amplified using a 
standard PCR technique and a pair of specific primers 
(Table 1). 
Protein isolation. Recombinant strains harboring H5- 
and chIL-2-coding genes were grown in CDM medium, 
to an optical density OD600 equal 0.6. Crude extracts 
were obtained by disrupting the cells at high speed using 
the Mini Bead Beater (MBB-8) device and glass beads 
(106-μm diameter; Sigma) 3 × for 1 min with 1-min in-
tervals, during which the cells were kept on ice. Cellular 
Table 1. Bacterial strain, plasmids and primers used in this study.
Bacterial strain Properties reference
IL1403 Laboratory, wild type, plasmid-free strain (Chopin et al, 1984)
Plasmids Properties reference
pIL253:PptcB EmR, pIL253-derivative with ptcB gene promoter region IBB PAS collection
pIL253:PptcB:H5 Em
R, pIL253-derivative with ptcB gene promoter region, enco-
ding H5 gene of H5N1 this work
pIL253:PptcB:H5His
EmR, pIL253-derivative with ptcB gene promoter region enco-
ding H5 gene of H5N1 fused with His-tag nucleotide sequence 
at C’ terminal end
this work
pIL253:PptcB:H5:chIL2 Em
R, pIL253-derivative with ptcB gene promoter region enco-







*Conditions for DNA amplification were determined depending on each primer and length of the amplified sequence. Sequences recognized by 
particular restriction enzymes are shown in bold. 
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debris and glass beads were removed by centrifugation 
for 10 min at 8 000 rpm. Protein concentrations were 
determined using Nano Drop (Thermo Scientific).
SDS/PAGE analysis of protein extracts. Equal 
volumes of 2× loading buffer (125 mM Tris/HCl pH 
6.8, 4% SDS, 10% β-mercaptoethanol, 20% glycerol, 
and 0.01% bromophenol blue) and protein extracts were 
combined. Subsequently, samples were incubated for 5 
min at 95°C and then cooled on ice for 5 min. Next, 
protein samples were analyzed by SDS/PAGE (110 V, 
500 mA, 2 h). Inclusion bodies obtained by over-expres-
sion of H5-coding gene in E. coli were used as a positive 
control for protein analysis. Negative standard protein 
samples obtained from IL1403 [pIL253:PptcB] were used 
for data normalization.
Western-blot analysis for H5 antigen. Proteins sep-
arated by SDS/PAGE were transferred onto nitrocellu-
lose Hybond-C Extra membranes (Amersham) at 45 A 
and constant V for 1 h using semi-dry blotter (Hoefer). 
Membranes were blocked overnight at 4ºC with TS buf-
fer (20 mM Tris, 0.13 mM NaCl, pH 8.0), containing 
3% skim milk. Immunoblotting was carried out using 
commercial monoclonal mouse antibodies against the H5 
antigen (Abcam), diluted at 1:1000.
Immunodetection was performed with secondary rab-
bit or mouse antibodies conjugated with alkaline phos-
phatase (Sigma) at dilution 1:30 000 and NBT/BCIP 
Stock Solution (Roche) as above. 
Dot blot detection of chIL2. Five µl of total protein 
extracts were deposited on a Hybond- C Extra nitrocel-
lulose membrane (Amersham). The dot-blot membrane 
was air-dried for 5 min, blocked at 37°C for 20 min in 
TS buffer (20 mM Tris, 0.13 mM NaCl, pH 8.0) contain-
ing 3% skim milk, and then incubated with chIL-2-spe-
cific commercial monoclonal antibodies (AbDserotec), at 
dilution 1:1000. Immunodetection was performed with 
secondary mouse antibodies conjugated with alkaline 
phosphatase (Sigma) at dilution 1:30 000 and NBT/BCIP 
Stock Solution (Roche) as recommended by the suppli-
ers. Negative standard protein samples obtained from 
IL1403 [pIL253:PptcB) were used for data normalization. 
Recombinant chicken interleukin-2 (PAP005 AbDSero-
tec) served as a positive control. 
Mouse immunization and sample collection. All 
work was performed ethically in compliance with the 
First Warsaw Local Ethics Committee for Animal Ex-
perimentation. Ten-week-old female BALB/c mice 
(Mossakowski Medical Research Centre of Polish Acad-
emy of Sciences, Warsaw, Poland), counting four groups 
of 5 mice each, were immunized intragastrically (i.g.) 
with 109 CFU of recombinant L. lactis expressing a sin-
gle H5 antigen (group 1), both H5 and chIL-2 proteins 
(group 2), with bacterial protein extract from IL1403 
[pIL253:PptcB:H5] (group 3), and with L. lactis carrying 
the empty vector [pIL253:PptcB] — control group. Same 
doses were administered to animals for the first three 
days of the trial, and then four times at 1-week intervals. 
Blood samples from the orbital sinus were collected four 
days after first three doses, six days after each subse-
quent booster, and 7 and 14 days after the last immuni-
zation. To obtain serum, whole blood samples were left 
to coagulate at room temperature for approximately 15 
to 30 minutes. The clot was rimmed using an applicator 
stick and then the sample was centrifuged twice at 4°C 
for approximately 10 min at 10 000 g. Obtained serum 
samples were stored at –80°C until assayed. 
Enzyme-linked immunosorbent assay (ELISA). 
Collected sera (15 µl) were assayed for the presence of 
antibodies against H5 antigen by an ELISA method, 
using MaxiSorp plates (Nunc) coated with mammalian 
cell-expressed H5 protein (17–530 aa, ∆RRRKKR) of 
A/Bar-headed Goose/Qinghai/12/05 (H5N1)) strain 
of influenza A virus (3 µg×ml–1) (Immune Technology). 
Secondary labeling and its detection were done with re-
agents purchased from Sigma-Aldrich. Serum samples 
from i.g. immunized mice with H5 harbored by L. lactis 
were tested in parallel with serum from sham-immunized 
mice (negative controls). Monoclonal antibodies to avi-
an influenza A virus (H5N1) HA (US Biological, Acris 
Antibodies) were used as positive controls. Experimental 
samples, diluted 1:25 in 2% BSA-PBS, positive controls 
and blanks (sample diluent) were applied onto the plates 
previously coated with H5 (3 µg×ml–1 in PBS, over-
night, 2–8ºC) and then incubated overnight at 2–8ºC. 
Antibody classes were detected with goat generated and 
horseradish peroxidase (HRP)-labeled antibodies against 
mouse IgG (γ-chain specific) and IgA (α-chain specif-
ic) at 1:500 dilution (1 h, 37ºC). In all tests performed, 
TMB was used as the substrate. After incubation for 30 
min at room temperature, the reaction was stopped by 
the addition of 0.5 M sulfuric acid. The absorbance was 
quantified at 450 nm with subtraction of the mean OD 
readings of blanks. Samples were considered to be posi-
tive for anti-H5 antibodies if the OD readings were 2SD 
above the mean OD readings of samples from control 
mice (cut-off value).
RESULTS
Recombinant H5 and chIL-2 expression in L. lactis
Expression of H5, H5 His-tag and chIL-2 genes un-
der the control of the ptcB promoter was attested by 
RT-PCR. The main products of 1.8 kb and 434 bp cor-
responding respectively to H5- and chIL-2-encoding re-
gions were identified (data not shown). No positive sig-
nals were noted for the negative control. Subsequently, 
specific positive signals on the translational level were 
detected in immunoenzyme reactions. However, Western 
blot analysis performed for the H5 protein revealed in-
tracellular proteolysis of the antigen, visible as a ladder 
on the nitrocellulose membrane. This degradation was 
also visible and confirmed for the His-tagged protein 
Figure 1.Western blot analysis of H5 production under ptcB pro-
moter with anti-His commercial antibodies.
Immunoblotting was carried out using H5 specific commercial 
monoclonal mouse antibodies (Abcam) diluted at 1:1000. Immu-
nodetection was performed with secondary mouse antibodies 
conjugated with alkaline phosphatase (Sigma) at dilution 1:30 000 
and a NBT/BCIP Stock Solution (Roche) as recommended by the 
suppliers. Intracellular proteolysis of the antigen was visible as a 
characteristic ladder of bands on the nitrocellulose membrane 
(lanes 1, 2, 3, 4, 5 — protein extracts of IL1403 [pIl253:PptcB:H5His] 
strain).  No specific products were observed for negative control 
— protein extract of IL1403 [pIl253:PptcB] (C–). 
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(Fig. 1). For the chIL-2 protein (Fig. 2), both the soluble 
and insoluble fraction samples gave positive signals, with 
a definitely stronger signal for samples enriched with the 
membrane fraction. The negative control did not react 
with the antibody. 
ELISA detection of H5-specific serum antibody
Immunogenicity of L. lactis-expressed H5 antigen was 
investigated in the mouse model. Recombinant bacteria 
in the form of live vector vaccine or protein extracts 
were administered by intragastric gavage using the same 
time scheme. In mice immunized with L. lactis expressing 
the H5 antigen alone (group 1), only weak serum IgG 
and IgA responses were observed (Fig. 3A and B). Only 
a single mouse responded slightly stronger with an IgG 
peak after administration of the third dose (Fig. 3A). 
Higher serum antibody responses were shown for mice 
in group 2, vaccinated with L. lactis co-expressing H5 and 
chIL-2. Antigen-specific IgG antibodies were detected in 
serums collected after the third and subsequent immu-
nizations (Fig. 4A) and for IgA isotype at different time 
points of the experiment (Fig. 4B). Three out of four 
mice in group 2 responded more effectively with serum 
IgG after the fourth booster (Fig. 4A). For two mice 
this was accompanied by increased IgA levels (Fig. 4B). 
The strongest response was induced using the protein 
extract from H5-producing L. lactis (group 3), yet, this 
effect was observed for only one out of four mice. In 
this case, IgG antibodies against H5 were detected in the 
serum after the fourth immunization and peaked 7 days 
after application of the fifth dose (Fig. 5A and B). This 
was not accompanied by IgA response. The remaining 
mice from group 3 did not develop anti-H5 antibodies. 
Samples from mice sham-immunized with the control 
strain gave low OD values, which were constant during 
the whole experiment. This is indicated in the figures as 
dashed cut-off lines. In summary, four mice developed 
more pronounced H5-specific IgG antibodies in sera af-
ter three-four boosters of recombinant L. lactis express-
ing H5 (Fig. 3A and Fig. 4A).
DISCUSSION
In this study, a new system of protein production in 
L. lactis has been tested. The idea was based on car-
bon catabolite repression operating in Gram-positive 
bacteria that is exerted through binding of the CcpA 
protein to cre, a cis-acting catabolite responsive ele-
ment (Aleksandrzak-Piekarczyk et al., 2005). CcpA can 
act as an activator of the promoter sequence of the 
regulated gene or an inhibitor. The promoter sequence 
of the chromosomal L. lactis ptcB gene, containing 
a cre sequence, was used to create the pIL253:PptcB 
vector to potentially increase heterologous protein 
production in transformed L. lactis strains. The ac-
tivity and efficiency of the ptcB promoter region was 
already described by Aleksandrzak-Piekarczyk et al., 
2011. To investigate the efficiency in immunoprotec-
tion against avian influenza virus, three L. lactis strains 
expressing genes for avian influenza virus H5 protein 
and chicken IL-2 from the pIL253:PptcB vector were 
analyzed. For this, recombinant bacteria in the form 
of live vector vaccine or protein extract were admin-
istered to BALB/c mice by intragastric gavage using 
the same time scheme. Serum antibody responses of 
IgG and IgA isotypes were monitored. These antibod-
ies are considered to be one of the most effective de-
Figure 2.Dot blot analysis for chIL-2 production in the IL1403 
[pIL253:PptcB:H5:IL-2] strain.
The dot-blot membrane was air-dried for 5 min, blocked with 10% 
nonfat dry milk blocking buffer at 37°C for 20 min, and then in-
cubated with the primary antibody using a chIL-2 specific com-
mercial monoclonal antibodies (AbDserotec), at dilution 1:1000, 
and with secondary mouse antibodies conjugated with alkaline 
phosphatase (Sigma) at dilution 1:30 000. Immunodetection was 
performed with NBT/BCIP Stock Solution (Roche) as recommend-
ed by the suppliers. Negative standard protein samples IL1403 
[pIL253:PptcB] were used for data normalization. C– (negative con-
trol), 1–2 and 5–6 soluble fraction; 3–4 and 7–8 insoluble, mem-
brane fraction, C+ (positive control).
Figure 3. Serum antibody response after immunization with L. lactis expressing H5 antigen.
Five mice were immunized seven times with 109 CFU of L. lactis [pIL253:PptcB:H5] on days indicated by arrows. Serum samples were col-
lected at various time points of the experiment. Levels of H5-specific IgG (A) and IgA (B) antibodies were determined in samples diluted 
1:25. Results obtained for immunized mice at each time point of blood sampling are shown individually (squares) and as mean OD val-
ues (dashes). The mean OD readings higher by 2 SD than control mice samples were considered as the cut-off indicated by the dashed 
line.
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fense mechanisms against respiratory infections and a 
vital attribute of any vaccine designed to prevent in-
fections (Lamm, 1997; Xi net al., 2003). Preliminary 
animal trial showed the capability of recombinant 
L. lactis strains producing the H5 antigen to evoke an 
immune response via the mucosal route. Moreover, 
antibodies induced with L. lactis-expressed H5 recog-
nize recombinant H5 of mammalian-cell origin, which 
has been shown to preserve essential epitopes of the 
native protein and its oligomeric structure (data not 
shown). The best immunization results were obtained 
with the use of a strain co-expressing H5 and chIL-2, 
as mice from this group gave the clearest response to 
vaccination as judged by IgG and IgA level of anti-H5 
antibodies (Fig. 4A and B). Overall, the enhanced im-
mune response observed in this animal group was pre-
sumably related to the presence of chIL-2, anticipated 
to play a role of an adjuvant. In particular, chIL-2 has 
been studied widely as an immuno-enhancer due to its 
role in activating T cell proliferation. The unsatisfac-
tory number of responder mice and overall low levels 
of serum H5-specific antibodies were probably, and 
at least partially, due to the low amounts of properly 
folded H5, caused by strong intracellular proteolysis 
of expressed antigen inside bacterial cells. The pro-
teolytic pattern of degradation observed for the het-
erologous protein is far different from that which oc-
curs during a natural viral infection of host cells. Such 
effect often leads to production of many undesirable 
epitopes which can be a response-limiting factor. On 
the other hand, strong serum antibody response is dif-
ficult to induce solely by the mucosal route and sev-
eral experiments are often needed to establish an ef-
fective immunization scheme.
In summary, our group demonstrated here the use 
of L. lactis as a biological host for production of viral 
antigen and chicken cytokine. The tested ptcB promoter 
region might be an attractive system for production of 
heterologous proteins. The results of the preliminary ani-
mal trial conducted in mice are a promising step toward 
development of a vaccine against avian bird flu using 
L. lactis cells as antigen carriers. 
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Figure 4. Serum antibody response after immunization with L. lactis expressing H5 and chIL-2.
Five mice were immunized seven times with 109 CFU of L. lactis [pIL253:PptcB:H5:IL-2] on days indicated by arrows. Serum samples were 
collected at various time points of the experiment. Levels of H5-specific IgG (A) and IgA (B) antibodies were determined in samples di-
luted 1:25. Results obtained for immunized mice at each time point of blood sampling are shown individually (diamonds) and as mean 
OD values (dashes). The mean OD readings higher by 2 SD than control mice samples were considered as the cut-off indicated by the 
dashed line.
Figure 5. Serum antibody response after immunization with protein extract from L. lactis expressing H5.
Five mice were immunized seven times on days indicated by arrows with protein extract obtained from IL1403 [pIL253:PptcB:H5] cor-
responding to 109 CFU. Serum samples were collected at various time points of the experiment. Levels of H5-specific IgG (A) and IgA 
(B) antibodies were determined in samples diluted 1:25. Results obtained for immunized mice at each time point of blood sampling are 
shown individually (triangles) and as mean OD values (dashes). The mean OD readings higher by 2 SD than control mice samples were 
considered as the cut-off indicated by the dashed line.
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